GLG News by Radiation Oncologists

Certainly, we've had a flurry of bad press over the last few years on blockbuster drugs that had unexpected consequences - Celebrex, ESAs (Epogen, Aranesp, etc...), and most recentlyl Avandia. Statins are some of the most widely used drugs in medicine in a multi-billion dollar industry. We know these...

Certainly, we've had a flurry of bad press over the last few years on blockbuster drugs that had unexpected consequences - Celebrex, ESAs (Epogen, Aranesp, etc...), and most recentlyl Avandia. Statins are some of the most widely used drugs in medicine in a multi-billion dollar industry.   ...

Patients with hormone refractory prostate cancer have few options for treatment, and can be a challenge to manage.   Taxotere has shown an overall survival benefit in this patient population, however, when patients become refractory to this, there are no real viable options. Many companies...

Another example of the erosion of a physicians autonomy. While recent data has suggested some concerns with the use of ESA's in cancer patients, the risk of cardiovascular and thromboembolic events was associated with HgB>12. Certainly, in the past we were less cautios about the HgB. CMS has now...

Erbitux has been very successful in the colorectal cancer and head and neck trials.   The EGFR receptor is prevalent in many malignancies, and represents an obvious direction to expand the use of erbitux in other malignancies - ie lung cancer, esophagus, etc. As more indications for erbtitux...

Let's face it - the rural US is a relatively 'undesirable' (please don't get offended) location, with little access to a big city or collegiality with other physicians.   It also poses a challenge, as there are limited access to specialists.    I suspect it's not a dream job...

New small molecule inhibitor of androgen receptor - mechanism not completely known, but likely similar idea to other small molecule inhibitors in development for other receptors. Target population is hormone refractory prostate cancer, for which there is little viable therapy.   This is the...

Reimbursement has continued to either remain flat or decline in the setting of rising office overhead costs.   Medicaid, which covers those that are the poorest with the least access to care provides even worse reimbursement. In the setting of being able to run a practice effectively, Medicaid...

First they want to keep cutting physician reimbursements like medicare, but when they realize medicare cuts may affect their ability to provide care for medicare patients, now they want raises? Certainly not a dime of what they want from the government will be put back in the pockets of physicians. ...

Chronic disease, by nature requires continuous management.    With disease such as diabetes, COPD, hypertension (and it's systemic manifestation), congestive heart failure and heart disease, many patients require round the clock medications, physician or nurse practioner management, and...